Press &
Media Coverage

FDA Clears CureMetrix's cmAngio 2.0, Introducing BAC Quantification and Age-Based Context

CureMetrix received FDA 510(k) clearance for cmAngio 2.0, an AI software that detects and quantifies breast arterial calcification on screening mammograms. The updated version adds quantitative measurement, age-based context, and prevalence information to help physicians provide patients with more meaningful health information.

Breast Center of New England Expands Personalized Breast Imaging Services with CureMetrix's cmAngio®

Breast Center of New England, a women-owned practice in New Hampshire, has adopted cmAngio®, an FDA-cleared AI tool for detecting breast arterial calcification from routine mammograms. The technology provides additional clinical insights without requiring extra imaging, radiation, or patient appointments.

Invision Diagnostics Expands Women's Health Offerings with CureMetrix's cmAngio®

CureMetrix and Cascaid Health Announce Collaboration to Support Coordination Following Radiologist-Reviewed BAC Findings

CureMetrix® Brings cmAngio® BAC Detection to Rezolut Imaging Patients